Post by Marken

Geopolitical instability is no longer a background risk for pharmaceutical supply chains. Life sciences organizations are being forced to rethink how they maintain continuity, preserve flexibility, and support patient access across increasingly interconnected global networks. In his latest interview with The Medicine Maker, Dan Bell, SVP, Drug Supply, Distribution & Advanced Therapies at Marken, discusses how pharmaceutical companies are responding to tariff volatility and shifting trade dynamics with more adaptive supply chain strategies. The conversation explores why resilience now depends on the ability to respond quickly to changing conditions without disrupting timelines, increasing risk, or compromising quality. As pressure on global supply chains continues to evolve, operational agility is becoming a long-term strategic advantage. Read the full article: https://lnkd.in/e3XpzH62 #PharmaLogistics #SupplyChain #Biopharma #HealthcareLogistics #ClinicalTrials #LifeSciences #TradeCompliance #Pharmaceuticals